Private equity firm Permira has agreed to acquire German speciality pharmaceutical company Neuraxpharm from Apax Partners.
The companies did not divulge financial details of the transaction.
Go deeper with GlobalData
According to Reuters citing those familiar with the matter, the deal values Neuraxpharm at approximately €1.6bn ($1.88bn), including debt.
Founded in 1985, Neuraxpharm develops and commercialises drugs and consumer healthcare products for central nervous system disorders.
The company works on products for chronic neurological and psychiatric disorders, including epilepsy, Parkinson’s disease, Alzheimer’s disease, depression and psychosis.
With more than €460m yearly revenues and approximately 850 employees, the speciality pharmaceutical firm has a significant footprint in Europe in many of its more than 115 CNS molecules.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataIn 2016, Apax purchased Neuraxpharm, merging it with Invent Farma, followed by add-on acquisitions such as FB Health and Farmax.
Permira expects to benefit from increased demand for Neuraxpharm’s antidepressants, painkillers and various other CNS medications, added Reuters.
Furthermore, Permira funds will allegedly help the pharmaceutical company grow further in Europe via commercialisation of its new pipeline and support for its international expansion strategy.
Permira DACH head Jörg Rockenhäuser said: “With our longstanding global track-record in successfully transforming market leaders and our proven expertise in the healthcare sector, the Permira funds will back Neuraxpharm to reach the next level of growth.
“Our joint goal is to create the leading European CNS speciality platform with further acquisitions and strong organic growth.”
The acquisition, subject to customary closing conditions, should conclude in the fourth quarter of this year.
In August last year, Permira signed a deal to acquire small molecule company Cambrex for approximately $2.4bn.
